Article
Regeneron drops after skin cancer treatment misses late-stage trial goal
Pessimistic
-25.0
−100 Bearish
0
+100 Bullish
The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS).
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
CNBC Top Stories
Published
May 18, 2026 · 10:49 am
Article ID
j6vv0xx
Original URL
Open source
Sentiment Signal
Pessimistic
-25.0
−100Neutral+100
More Like This